Transforming Urologic Care in Philadelphia and Worldwide. The Fox Chase – Temple Urologic Institute.
Urologic Institute Leaders:
OR, Clinic, Bench, and Bedside
• The Institute’s extensive surgical options include
robotics, focal therapy, and complex open procedures.
• International experts offer urethral reconstruction, penile
prosthetics, intra-abdominal reconstructions, and female
pelvic reconstruction.
• Elite residency and fellowship programs train
future leaders.
• Globally recognized for expertise in kidney cancer,
bladder cancer, and interstitial cystitis.
• One of the country’s largest bladder preservation
programs through light cystoscopy (Cysview) and
intravesical therapy.
• Inventor of the seminal R.E.N.A.L Nephrometry score to
categorize renal masses.
• At the forefront of bladder preservation trials such as
RETAIN and INSITE.
In just four years, the Fox Chase – Temple Urologic Institute has leveraged the expertise of two renowned institutions to deliver an exceptionally broad range of aligned and specialized urology and urologic oncology services, led by eminent clinicians and thought leaders.
#1 in Pennsylvania for kidney cancer and bladder cancer surgical volumes.*
The Institute combines the depth of expertise of Fox Chase Cancer Center—an NCI-designated Comprehensive Cancer Center—with the resources of Temple Health, a leading academic health system with a long-standing urology program that performs thousands of procedures each year across the full spectrum of urologic conditions.
The Institute offers easy access to an unprecedented level of comprehensive urologic care from globally recognized specialists. Fox Chase also provides access to advanced treatments and novel clinical trials as well as a smooth transition to integrated urologic oncology and radiation oncology, rapidly drawing patients from the Philadelphia region, the country, and abroad.
* Pennsylvania Hospitals and Ambulatory Surgical Center 2025 data
Explore Fox Chase Genitourinary Clinical Trials
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
Investigator: Alexander Kutikov, MD, FACS
ClinicalTrials.gov ID: NCT06396533
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy.
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
Investigator: Andres F. Correa, MD
ClinicalTrials.gov ID: NCT07000084
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette-Guérin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).
Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
Investigator: Mark A Hallman, MD, PhD
ClinicalTrials.gov ID: NCT07219303
The goal of this clinical trial is to evaluate whether adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
Fox Chase Cancer Nomograms: Cutting-Edge Predictive Disease Modeling
What is the likelihood of a patient’s kidney, testicular, or prostate cancer recurring? Fox Chase Cancer Nomograms utilize multiple-site, disease-specific data to predict the likelihood of a specific outcome based on research from top scientific publications.
HOW TO REFER
To refer a patient, please call 888-FOX-CHASE (888-369-2427) or visit FoxChase.org/Refer.
CONTACT OUR TEAM
Our Key Account Managers can offer a seamless introduction to our specialists, obtain a patient appointment, and answer any questions or concerns you have. Contact our team at KeyAccountManager@fccc.edu.